Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 7Tumor-Agnostic 6Thoracic 6Gastrointestinal 5Head & Neck 3Gynecologic 3Breast 3Endocrine 2Dermatologic 2Sarcoma 1NET 1CNS 1

Conditions

Neuroendocrine Tumors 4Carcinoma, Neuroendocrine 3Neoplasms 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Lymphoma, Follicular 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × avelumab × Endocrine × Clear all
NCT03352934 2022-02-25

AveNEC

Johannes Gutenberg University Mainz

Phase 2 Completed
60 enrolled
EndocrineNET

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01772004 2021-12-20

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

EMD Serono

Phase 1 Completed
1,756 enrolled 59 charts
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡